Kiniksa Pharmaceuticals (KNSA)

• Market cap: $6.1B
• 1 day: -3.36%
• 5 days: 23.44%
• 1 month: 22.28%
• 3 months: 45.41%
• 6 months: 78.05%
• Year to date: 86.15%
• 1 year: 160.15%
• 5 years: 410.11%
• 10 years: 301.64%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Employees: 366